EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Empagliflozin versus sitagliptin for ameliorating intrahepatic lipid content and tissue‐specific insulin sensitivity in patients with early‐stage type 2 diabetes with non‐alcoholic fatty liver disease: A prospective randomized study

Shigenori Hiruma, Fumika Shigiyama, Naoki Kumashiro iD

Diabetes, Obesity and Metabolism · 2023

DOI: 10.1111/dom.15006 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2023. Verfasst von Shigenori Hiruma und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Diabetes, Metabolism, and Endocrinology, Department of Medicine, Toho University Graduate School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Non-alcoholic Fatty Liver Disease, Insulin Resistance, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To compare the effects of sodium‐glucose co‐transporter‐2 (SGLT2) inhibitors and dipeptidyl peptidase‐4 inhibitors on ectopic fat accumulation and tissue‐specific insulin sensitivity. Materials and Methods This randomized controlled trial enrolled 44 patients with type 2 diabetes (T2D) and non‐alcoholic fatty liver disease (NAFLD). They were randomly assigned to receive either empagliflozin 10 mg/day or sitagliptin 100 mg/day for 12 weeks. The primary endpoint was the change in intrahepatic lipid content (IHL) measured using proton magnetic resonance spectroscopy ( 1 H‐MRS). The secondary endpoints included intramuscular and extramuscular lipid content seen in 1 H‐MRS, body composition seen through dual‐energy X‐ray absorptiometry and tissue‐specific insulin sensitivity shown through hyperinsulinaemic‐euglycaemic clamp using stable isotopic glucose. Liver biopsy samples were pathologically evaluated at baseline.

Results

At baseline, the mean duration of diabetes, HbA1c level and IHL were 3.7 years, 7.2% and 20.9%, respectively. The median NAFLD activity score was 3.0. IHL was significantly more decreased in the empagliflozin group than that in the sitagliptin group (between‐group difference was −5.2% ± 1.1% and −1.9% ± 1.2%, respectively, (95% confidence interval); −3.3 (−6.5, −0.1), P = .044). However, there were no significant between‐group differences in the change of insulin sensitivity in the liver, muscle or adipose tissues. Interestingly, hepatic insulin sensitivity was significantly increased only in the empagliflozin group and was significantly negatively associated with the change in IHL.

Conclusions

Empagliflozin significantly improves hepatic steatosis compared with sitagliptin, and this may protect against subsequent hepatic insulin resistance. Early administration of SGLT2 inhibitors is preferable for T2D patients with NAFLD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Non-alcoholic Fatty Liver DiseaseInsulin ResistanceSodium-Glucose Transporter 2 InhibitorsHumansSitagliptin PhosphateProspective StudiesGlucoseLipidsBenzhydryl CompoundsGlucosides

Stichwörter der Autor:innen

DPP-IV inhibitorSGLT2 inhibitorclinical trialfatty liver diseaseinsulin resistancetype 2 diabetes

Substanzen

Sitagliptin PhosphateSodium-Glucose Transporter 2 InhibitorsGlucoseLipidsempagliflozinBenzhydryl CompoundsGlucosides

Autor:innen und Institutionen

  • Division of Diabetes, Metabolism, and Endocrinology, Department of Medicine, Toho University Graduate School of Medicine, Tokyo, Japan.
  • Department of Diabetology and Endocrinology, Kanazawa Medical University, Ishikawa, Japan.

ORCID-Profile: Naoki Kumashiro

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Hiruma, S., Shigiyama, F., & Kumashiro, N. (2023). Empagliflozin versus sitagliptin for ameliorating intrahepatic lipid content and tissue‐specific insulin sensitivity in patients with early‐stage type 2 diabetes with non‐alcoholic fatty liver disease: A prospective randomized study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15006

Vancouver

Hiruma S, Shigiyama F, Kumashiro N. Empagliflozin versus sitagliptin for ameliorating intrahepatic lipid content and tissue‐specific insulin sensitivity in patients with early‐stage type 2 diabetes with non‐alcoholic fatty liver disease: A prospective randomized study. Diabetes, Obesity and Metabolism. 2023. doi:10.1111/dom.15006

BibTeX
@article{Hiruma2023,
  author = {Hiruma, Shigenori and Shigiyama, Fumika and Kumashiro, Naoki},
  title = {Empagliflozin versus sitagliptin for ameliorating intrahepatic lipid content and tissue‐specific insulin sensitivity in patients with early‐stage type 2 diabetes with non‐alcoholic fatty liver disease: A prospective randomized study},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2023},
  doi = {10.1111/dom.15006}
}
Kostenlos starten →